IL-17抑制剂塞库金努马布在复发性多合体炎中实现缓解:一个病例报告
Stefka Neycheva1, Adriana Kamburova1
1Department of Rheumatology, Military Medical Academy, Sofia, Bulgaria.
The American journal of case reports
|March 20, 2025
概括
一个罕见的自身免疫性疾病 - - 复发性多合体炎,在一个具有挑战性的病例中,成功地使用了介质蛋白-17 (IL-17) 抑制剂来治疗. 这种新的方法在复发性多体炎和同时存在的化脊柱炎中实现了缓解.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 复发性多合体炎 (RP) 是一种罕见的自身免疫性疾病,其原因不明,没有确定的治疗方案.
- 治疗RP往往依赖于医生的经验,常规疾病修饰性抗风湿药物 (DMARD) 报告的疗效有限,生物药物的结果可变.
- 该案涉及一名32岁的女性,她有结性脊柱炎病史,在第二次分娩后出现了侵袭性,耐火性RP.
研究的目的:
- 报告一种新的治疗方法,用于与结性脊柱炎并存的侵袭性,耐火性复发性多重体炎.
- 为了评估一种干白素-17 (IL-17) 抑制剂在治疗双重自身免疫性疾病中的有效性.
- 为了解罕见自身免疫性疾病的治疗选择做出贡献.
主要方法:
- 一份病例报告,详细介绍了患有结性脊柱炎和复发性多重体炎同时存在的患者的临床过程和治疗方法.
- 记录了使用抗TNFαα抑制剂和甲铁沙的初始治疗失败.
- 通过使用IL-17抑制剂secukinumab获得了成功的治疗.
主要成果:
- 这位患者在冠状腺炎发作之前呈现了结性脊柱炎的高疾病活性 (ASDAS-CRP 3.5,BASDAI 6.0).
- 传统的治疗方法,包括抗TNFαα抑制剂和甲状腺素,证明是无效的.
- 一种IL-17抑制剂Secukinumab在复发性多合体炎和结性脊柱炎中成功诱导了缓解.
结论:
- 需要进一步的研究来阐明复发性多重合体炎的发病原因.
- 生物制剂,包括IL-17抗剂在RP治疗中的有效性需要进一步研究,解决有关潜在副作用与独立疾病发生问题的问题.
- 这一案例代表了第一个成功使用抗IL-17药物 (secukinumab) 抑制侵袭性,渐进性复发性多重合体炎的报告.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
123
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
123
T Cell Types and Functions
730
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
730
Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83


